Claims (14)
1. Protutijelo koje se specifično veže na ljudski TNFα, naznačeno time, da obuhvaća sljedeće:
a) varijabilni laki lanac koji sadrži sekvencu od SEQ ID NO: 2 ili SEQ ID NO: 14; i
b) varijabilni teški lanac koji sadrži sekvencu od SEQ ID NO: 5.1. An antibody that specifically binds to human TNFα, characterized in that it comprises the following:
a) variable light chain containing the sequence of SEQ ID NO: 2 or SEQ ID NO: 14; and
b) a variable heavy chain containing the sequence of SEQ ID NO: 5.
2. Protutijelo prema zahtjevu 1, naznačeno time, da sadrži poveznicu koja obuhvaća sekvencu od SEQ ID NO: 7.2. The antibody according to claim 1, characterized in that it contains a linker comprising the sequence of SEQ ID NO: 7.
3. Protutijelo prema zahtjevu 1, naznačeno time, da protutijelo obuhvaća sekvencu od SEQ ID NO: 10 ili SEQ ID NO: 17.3. The antibody according to claim 1, characterized in that the antibody comprises the sequence of SEQ ID NO: 10 or SEQ ID NO: 17.
4. Farmaceutski pripravak, naznačen time, da obuhvaća terapeutski učinkovitu količinu protutijela prema bilo kojem od zahtjeva 1 do 3 i farmaceutski prihvatljiv nosač.4. A pharmaceutical preparation, characterized in that it comprises a therapeutically effective amount of the antibody according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.
5. Farmaceutski pripravak prema zahtjevu 4, naznačen time, da se upotrebljava za liječenje bolesti posredovane putem TNFα.5. Pharmaceutical preparation according to claim 4, characterized in that it is used for the treatment of a disease mediated by TNFα.
6. Farmaceutski pripravak prema zahtjevu 4, za uporabu prema zahtjevu 5, naznačen time, da se kod bolesti koja je posredovana putem TNFα, radi o očnom poremećaju odabranom iz skupine koju čine: uveitis, Bechetova bolest, retinitis, suho oko, glaukom, Sjögrenov sindrom, dijabetska neuropatija, skleritis, makularna degeneracija povezana sa starosnom dobi i keratitis.6. Pharmaceutical preparation according to claim 4, for use according to claim 5, characterized in that the disease mediated by TNFα is an eye disorder selected from the group consisting of: uveitis, Bechet's disease, retinitis, dry eye, glaucoma, Sjögren's syndrome, diabetic neuropathy, scleritis, age-related macular degeneration and keratitis.
7. Farmaceutski pripravak prema zahtjevu 4, za uporabu prema zahtjevu 5, naznačen time, da se farmaceutski pripravak treba davati putem sljedećih primjena: okularna, intranazalna, otička, sublingvalna, transdermalna, topikalna, oralna, nazalna, rektalna ili parenteralna.7. Pharmaceutical preparation according to claim 4, for use according to claim 5, characterized in that the pharmaceutical preparation should be administered through the following applications: ocular, intranasal, otic, sublingual, transdermal, topical, oral, nasal, rectal or parenteral.
8. Farmaceutski pripravak prema zahtjevu 7, za uporabu prema zahtjevu 7, naznačen time, da se farmaceutski pripravak treba davati u jednostrukoj ili podijeljenoj dozi koja sadrži od 0,1 do 100 mg protutijela.8. Pharmaceutical preparation according to claim 7, for use according to claim 7, characterized in that the pharmaceutical preparation should be administered in a single or divided dose containing from 0.1 to 100 mg of antibody.
9. Farmaceutski pripravak prema zahtjevu 7, za uporabu prema zahtjevu 7, naznačen time, da se kod bolesti koja je posredovana putem TNFα, radi o uveitisu, a farmaceutski pripravak se primjenjuje topikalno u oko pojedinca.9. Pharmaceutical preparation according to claim 7, for use according to claim 7, characterized in that the disease mediated by TNFα is uveitis, and the pharmaceutical preparation is applied topically to the individual's eye.
10. Izolirana molekula nukleinske kiseline, naznačena time, da ona kodira protutijelo prema zahtjevu 1.10. An isolated nucleic acid molecule, characterized in that it encodes an antibody according to claim 1.
11. Vektor, naznačen time, da on obuhvaća molekulu nukleinske kiseline prema zahtjevu 10.11. Vector, characterized in that it comprises a nucleic acid molecule according to claim 10.
12. Stanica domaćina, naznačena time, da ona obuhvaća vektor prema zahtjevu 11.12. The host cell, characterized in that it comprises the vector according to claim 11.
13. Protutijelo prema zahtjevu 1, naznačeno time, da protutijelo je Fab, Fab’, F(ab)’2, Fv jednostrukog lanca (scFv), Fv fragment, ili linearno protutijelo.13. Antibody according to claim 1, characterized in that the antibody is Fab, Fab', F(ab)'2, Fv single chain (scFv), Fv fragment, or linear antibody.
14. Bivalentna ili bispecifična molekula, naznačena time, da ona obuhvaća protutijelo prema zahtjevu 1.14. Bivalent or bispecific molecule, characterized in that it comprises an antibody according to claim 1.